跳至主要内容
临床试验/NCT01586091
NCT01586091已完成4 期

Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response

Charite University, Berlin, Germany1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2011年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
18
试验地点
1
主要终点
Pruritus as Assessed by the VAS Score

研究概览

简要总结

This Study is to comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg once daily with Fexofenadine 60 mg twice daily in the histamine induced wheal, flare and itch Response.

详细描述

This will be a randomized, double-blind, placebo-controlled study with intra-individual comparison of the histamine induced wheal and flare reaction. In September 2009, Fexofenadine was approved as an antihistamine against allergies in Japan and it is currently used widely. It has been approved in 120 countries, including the US, UK, France and Germany [11]. In Europe and the United States, fexofenadine is marketed at 120 mg once daily for allergic rhinitis and 180mg once daily for urticaria. In Japan, fexofenadine is marketed at 60 mg twice daily for both conditions. But is this dosage regimen as effective as levocetirizine, 5 mg once daily? The above described study from Takahashi et al, comparing 60 mg twice daily versus cetirizine 10 mg once daily suggests that it is not [4]. The aim of the study is to compare the efficacy and consistency of action of levocetirizine 5 mg once daily with fexofenadine 60 mg twice daily over a 24 hour period in the histamine induced wheal, flare and itch response. Furthermore, we would like to investigate whether a different between Japanese and Caucasian exists or not. Each volunteer will receive the study medication at time point 0 and 12 hour later. Skin Prick Test (SPT) will be performed in each volunteer using histamine (10 mg/ml), 15 minutes before drug admission (baseline) and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours afterwards. Volumetric optical scanning system and infrared camera will be used for objective evaluation of the wheal- and flare reduction. Additionally, measurement of the erythema diameter with a transparent ruler will be performed. The subjective intensity of itching will be assessed using a Visual Analogue Scale (VAS). To relate the pharmacokinetics of the drugs to their pharmacodynamics, blood samples for assay of drug concentrations will be taken at baseline and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 hours later. Subjects will undergo the same procedure on three separate occasions to receive each treatment option. The options are: placebo at time 0 hours + placebo at 12 hours, Levocetirizine 5mg at time 0 hours + placebo at 12 hours or fexofenadine 60mg at time 0 hours + fexofenadine 60mg at 12 hours. There will be a washout period of at least 6 days between the treatments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Eighteen (18) healthy male volunteers, including at least 6 persons of Japanese origin, will be recruited for this study

排除标准

  • None of the subjects will have taken oral antihistamines, antidepressants, antipsychotics or corticosteroids or applied topical antihistamines, corticosteroids or mast cell stabilizers to the skin for 2 weeks prior to testing.
  • No subject shall perform physical exercise for 4 hours prior to the skin prick testing.
  • Especially, Bronchial asthma, anaphylactic reactions in the history, use of beta-blockers, skin diseases in the test field are exclusion criteria.

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo per os at time 0 hours + placebo per os at 12 hours.

干预措施: Placebo Oral Tablet (Drug)

Levocetirizin

Active Comparator

Levocetirizin 5mg at time 0 and placebo per os at 12 hours

干预措施: Levocetirizine Oral Tablet (Drug)

Levocetirizin

Active Comparator

Levocetirizin 5mg at time 0 and placebo per os at 12 hours

干预措施: Placebo Oral Tablet (Drug)

Fexofenadine

Active Comparator

Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours

干预措施: Fexofenadine 60 Mg Oral Tablet (Drug)

结局指标

主要结局

Pruritus as Assessed by the VAS Score

时间窗: up to 10 minutes after skin prick test performed 24 hours after drug administration

We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a "0" and "100" at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point.

Flaire Diameter (mm)

时间窗: 24 hours per treatment

Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this.

Wheal Volume (cm3)

时间窗: 24 hours per treatment

Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany).

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Martin Metz

Prof. Dr. med.

Charite University, Berlin, Germany

研究点 (1)

Loading locations...

相似试验

Safety Study of Levocetirizine and Fexofenadine | 临床试验